DruSO-CU: Determinants of omalizumab drug survival in a long-term daily practice multicentre cohort of patients with Chronic Urticaria

This international, multi-center, retrospective cohort study aims to investigate effectiveness and safety of omalizumab in a large multicenter cohort of patients with CU by using drug survival analysis. Furthermore, this study aims to identify the determinants of drug survival.

Study type: multi-center daily practice cohort study

We intend to present the study results at international congresses (preferably EADV and/or EAACI) and to publish them in high impact peer-reviewed scientific journals. To become a coauthor, you need to participate in the project and contribute to sufficient patient recruitment (both quantity and quality), the interpretation of the study results and manuscript development. Participation is feasible for centers with CU patient populations treated with omalizumab of n > 100 and the guarantee that data can be provided for all patients, to avoid selection bias.

Deadline: finish patient inclusion; July 22nd, 2022 anticipated

Are you interested in participating in the study? Please visit our member’s areaor send an Email (h.rockmann@umcutrecht.nl) for additional information.

Professor Marcus Maurer is joined by Dr Emek Kocatürk Göncü who addresses concerns regarding the impact of COVID-19 infection in patients with chronic urticaria and summarises the results of the recent UCARE project, PREG-CU.

 

Link: https://www.medthority.com/csu-learning-zone/podcast-series/

Read more

For many years, antihistamines have been a cornerstone of chronic urticaria therapy, but is there room for improvement? In this episode, Professor Martin Church reflects on the enormous progress that has been made in the field of urticariology over the course of his career and discusses what is yet to come for patients with this devastating disease.

Link:...

Read more

Professor Marcus Maurer is joined by “UCARE father”, Dr Luis Felipe Ensina, to discuss the frequently underestimated burden of urticaria, which Dr Ensina explains is not limited to the patients themselves, but may indirectly impact numerous friends and family members as well.

Read more

Contact us

GA²LEN coordinating Office
c/o DGAKI
Robert-Koch-Platz 7
10115 Berlin, Germany

UCARE office
Laura Schwenner

info(at)ga2len-ucare.com